Merck’s Licensing Philosophy Mixes Acquisitions And Development Deals
Executive Summary
Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005, in line with its projections of about 50 deals (1"The Pink Sheet" Jan. 10, 2005, p. 35). Merck VP & Chief Licensing Officer Barbara Yanni recently sat down with "The Pink Sheet" DAILY to outline the company's licensing strategy and talk about plans for future growth.